Ono Bulks Up MAb R&D With Second Swiss Biotech Deal

Human-derived monoclonal antibodies targeted against neurodegenerative diseases is the subject of a deal between Japan's Ono Pharmaceutical and Zurich-based biotech Neurimmune.